AstraZeneca-CICC Venture Capital
VC Fund
Beijing, China
AstraZeneca-CICC Venture Capital is a Global Healthcare Industrial Fund formed by AstraZeneca and China International Capital Corporation.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries AstraZeneca-CICC Venture Capital invests in
Stages AstraZeneca-CICC Venture Capital invests in
Countries AstraZeneca-CICC Venture Capital invests in
Investment Focus
Industry
- Biotechnology 3 (60%)
- Biopharma 2 (40%)
- Medical 1 (20%)
- Pharmaceutical 1 (20%)
Stage
- Series B 2 (40%)
- Series C 1 (20%)
Country
- China 2 (40%)
- United States 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
YolTech Therapeutics
|
Yaotang (Shanghai) Biotechnology is a high-tech biotechnology company focusing on developing a new generation of mRNA drugs and gene editing drugs by combining mRNA in vivo delivery technology and gene editing technology. Through the continuous development and optimization of CRISPR, base editing and other new-generation gene editing tools, andinnovative improvements to the next-generation mRNA production platform and lipid nanocarrier assembly process, Yaotang Bio is committed to developing treatments for genetic diseases and cardiovascular disease. | $42.1M / Series B / Sep 11, 2025 | |
|
YolTech Therapeutics
|
Yaotang (Shanghai) Biotechnology is a high-tech biotechnology company focusing on developing a new generation of mRNA drugs and gene editing drugs by combining mRNA in vivo delivery technology and gene editing technology. Through the continuous development and optimization of CRISPR, base editing and other new-generation gene editing tools, andinnovative improvements to the next-generation mRNA production platform and lipid nanocarrier assembly process, Yaotang Bio is committed to developing treatments for genetic diseases and cardiovascular disease. | $42.1M / Series B / Sep 11, 2025 | |
Cullgen
|
Cullgen is a drug discovery service intended to create new drugs for the treatment of diseases that currently lack effective therapies. The company's services use protein degradation technology that focuses on the selective degradation of disease-causing proteins, a novel treatment for cancer, inflammatory and autoimmune diseases, includingtargets previously considered undruggable, enabling scientists with new means to develop novel therapeutic approaches for various diseases. | $35M / Series C / May 08, 2023 | |
|
Cullgen
|
Cullgen is a drug discovery service intended to create new drugs for the treatment of diseases that currently lack effective therapies. The company's services use protein degradation technology that focuses on the selective degradation of disease-causing proteins, a novel treatment for cancer, inflammatory and autoimmune diseases, includingtargets previously considered undruggable, enabling scientists with new means to develop novel therapeutic approaches for various diseases. | $35M / Series C / May 08, 2023 | |
Etern
|
Etern is developing small molecule drugs for protein liquid-liquid phase separation, using the LLPS platform for AI-enabled target discovery, high-throughput screening, and optimization. This could open new treatment strategies for major diseases. | Series B / Aug 31, 2021 |
Co-Investors
Green Pine Capital Partners
4 deals together
Decheng Capital
2 deals together
GNI Japan
2 deals together
Grand Flight Investment
2 deals together
Guoke New Energy Venture Capital
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does AstraZeneca-CICC Venture Capital invest in?
AstraZeneca-CICC Venture Capital invests primarily in Biotechnology, Biopharma and Medical startups, most often at Series B and Series C stage. Most of the 5 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did AstraZeneca-CICC Venture Capital last invest?
The most recent investment recorded for AstraZeneca-CICC Venture Capital closed in Sep 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
